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Patient-derived xenograft (PDX) models have become an important asset in translational cancer research. However, to provide a
robust preclinical platform, PDXs need to accommodate the tumor heterogeneity that is observed in patients. Colorectal cancer
(CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features. Surprisingly,
using a set of CRC patients, we revealed the partial representation of tumor heterogeneity in PDX models. The epithelial subtypes,
the largest subgroups of CRC subtype, were very ineffective in establishing PDXs, indicating the need for further optimization to
develop an effective personalized therapeutic approach to CRC. Moreover, we showed that tumor cell proliferation was associated
with successful PDX establishment and able to distinguish patient with poor clinical outcomes within CMS2 group.
Only ~7% of new cancer drugs entering phase I clinical trial
gain market approval, mainly due to the lack of efficacy and
robust preclinical data.1,2 This high failure rate underscores
the need for more clinically predictive models. Directly iso-
lated from cancer patients and transplanted into mice,
patient-derived xenografts (PDXs) have the potential to fill
this gap. In this role, PDXs have been used to identify novel
therapeutic targets and resistance biomarkers that cell lines
failed to capture.3–5 Accordingly, PDXs are advocated as reli-
able avatars of individual tumors by faithfully recapitulating
the biological characteristics and genetic heterogeneity within
tumors.6,7 However, it remains an open question as to what
extent PDXs represent the heterogeneity observed between
patients, which is especially relevant when considering the fact
that not all tumors can successfully generate a PDX. Colorec-
tal cancer (CRC) is a heterogeneous disease that can be strati-
fied into four consensus molecular subtypes (CMS) with
distinct biological features and clinical outcomes.8 CMS strati-
fication has the potential to transform CRC treatment by
matching drug efficacy with cancer subtype.9 To achieve this
goal, it is essential to recapitulate patient subtypes in preclini-
cal models. We, therefore, explored the factors contributing to
successful PDX establishment in CRC and particularly exam-
ined whether all subtypes are adequately represented in PDXs.
We subcutaneously implanted 42 surgically resected
tumors into immune-deficient mice (Fig. 1a, Supporting
Information Fig. S1a). These tumors represented CRC diver-
sity in terms of patient characteristics, such as stage, size, and
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CMS (Fig. 1b, Supporting Information Table S1). We achieved
a PDX take rate of 52% (22% total, 10% primary, and 12%
metastatic lesions), which is slightly lower as compared to a
previous PDX study using the same mouse strain (63.5%).7 Occa-
sional lymphoma formation was detected (7% of cases), likely
representing outgrowth of EBV+ B cells as previously described.10
Metastatic origin of the tumor was significantly associated with
engraftment success (Fischer’s exact test, p = 0.028), whereas
none of the other clinicopathological and (epi)genetic parameters
showed a significant correlation (Fig. 1c). Comparison between
PDX models and their corresponding donors showed that PDX
models retain patient histopathological and molecular features
(Supporting Information Figs. S1b–S1d).
CMS classification was obtained for the patients for which
expression data could be generated (N = 34). For 33 out of
34 patients, reliable classification was achieved and the sub-
type ratios were in accordance with the ratios previously
described.8 Strikingly, when engraftment success was evalu-
ated, CMS1 and CMS4 were shown to be more efficient than
the epithelial subtypes CMS2 and CMS3 (Fig. 1d, left). This
also holds when analyzing PDX establishment from primary
tumor origin only (Fig. 1d, right), indicating that CMS2/3
cancers displayed a lower engraftment success. The enrich-
ment toward CMS1 and CMS4 became even more prominent
when considering the capacity to serially engraft for at least
three passages. The large majority of CMS4 tumors (78%)
reached passage three (F3), whereas CMS2 tumors, the largest
subgroup in CRC, had a much lower efficacy (13%) (Fig. 1e).
Similar to CMS2, only 20% of CMS3 tumors reached F3,
whereas 75% of CMS1 engrafted successful, suggesting an
engraftment bias against the epithelial subtypes (CMS2 and
CMS3). Here, it is also evident that the engraftment success as
measured by propagation to passage 3 is significantly higher from
metastases-derived samples as compared to primary samples.
However, even within the metastasis group, we observe that only
1 in 4 CMS2 samples reached passage 3, whereas 6 out of
6 CMS4 samples were successfully engrafted. Consequently,
CMS4- and CMS1-derived PDXs were overrepresented at later
passages, increasing from 39% in the patient population to 77% of
F3 PDX models (Fig. 1f). We did not observe a clear difference in
growth speed across subtypes. As shown before,11 growth speed
accelerated with increased passaging (F2–F3) (Supporting Infor-
mation Figs. S1e and S1f), which likely represents an adaptation
to the xenotransplantation conditions. Both the subtype-specific
PDX engraftment efficiency and the subsequent serial passaging
efficiency challenge the design of preclinical PDX trials. Tradi-
tionally, tumor pieces are transplanted into a limited number
of mice to generate a PDX repository, which is then serially
expanded into a large number of mice in order to create a
sufficient statistical power to detect the differences between
treated and control group.12 Our study suggests that this typi-
cal design is not equally suitable for all tumor subtypes and
selects against the most prevalent subtype CMS2, which cannot
be efficiently propagated.
To further investigate the underpinnings of the differential
engraftment potential, we compared gene expression from
tumors with and without successful engraftment (Fig. 2a).
Gene set enrichment analysis (GSEA) revealed that cell cycle
activity/proliferation was significantly down-regulated in
tumors with successful engraftment, suggesting that tumors
with high proliferative capacity failed to engraft (Fig. 2b and
2c). This difference was also evident in tumors that managed
to propagate until F3 (Supporting Information Fig. S1g). To
confirm this, the level of the cell cycle-related protein Ki6713
was measured. Consistent with the gene expression analysis,
the number of Ki67+ cells was negatively correlated with
engraftment success (Figs. 2d and 2e). This is in line with the
observation that CMS2 cancers, which engraft poorly, display
high cell cycle-related gene expression compared to CMS4
cancers.8 However, closer examination of Ki67 expression
levels within CMS2 tumors showed that PDX establishment is
not simply a corollary of differences between CMS2 and
CMS4 tumors. In fact, it revealed that low tumor proliferation
is a predictor of engraftment success in CMS2 cancers
(Fig. 2f ). As PDX establishment has been linked to patient
outcome,14 we investigated whether this observation is clini-
cally relevant and can be exploited to stratify patients. We
found that low Ki67 gene expression was prognostic for recur-
rences when analyzing 741 stage II CRC patients (HR = 1.76,
p < 0.006; Fig. 2g), but showed a much stronger, but also vari-
able, prognostic value when analyzed per subgroup. Indeed,
further segregation into distinct subtypes indicated that low
Ki67 was not predictive for all subtypes. Although CMS1 and
CMS4 patients did not show a significant association of Ki67
with recurrence, a strong prognostic effect was detected in
CMS2 cancers, which had a higher propensity to recur when
Ki67 was low (HR = 2.43, p < 0.009) (Fig. 2h). Surprisingly,
the picture for CMS3 cancers showed the exact opposite, that
is, positive correlation of Ki67 expression with recurrence
(HR = 0.14, p < 0.01). Cell cycle activity is therefore an
What’s new?
Patient-derived xenograft (PDX) models have become an important asset in translational cancer research. However, colorectal cancer
(CRC) can be stratified into four consensus molecular subtypes (CMS) with distinct biological and clinical features, and to what
extent the existing CRC PDX collection represents the inter-patient heterogeneity remains an open question. This study identifies a
subtype-specific bias in the establishment of PDXs from CRC patients, leaving the major subtype CMS2 strongly underrepresented.
Additionally, the findings suggest that further classification within CMS can be achieved. For CMS2, the proliferation-related marker
Ki67 may thus help refine patient classification, estimate prognosis, and guide treatment decisions.
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Figure 1. Establishment of PDX model. (a) Schematic of the pipeline employed in the establishment of PDX models. (b) Gene expression heatmap and
corresponding genetic profile of tumors used to establish PDX. (c) Association of patients’ characteristic with engraftment success. (d) CMS1 and CMS4
were associated with engraftment success compared to CMS2/3. Figures shown is CMS distribution in all samples (left) and primary tumors (right). (e)
Detailed evaluation for each subtypes revealed that CMS1 and CMS4 could be efficiently passaged until third passage while most of CMS2/3 tumors could
not pass the second round of passage. (f) Comparison of subtype ratios between reported patient cohort,8 patient in our study and the corresponding
rounds of passage showed enrichment of CMS1 and CMS4 with increasing passage number. [Color figure can be viewed at wileyonlinelibrary.com]
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important prognostic factor, but it should be used with cau-
tion and in a subtype-specific manner. Heterogeneity of clini-
cal outcome within subtype was previously suggested when
analyzing the oxaliplatin response in patients15 and may pro-
vide the first hint that further stratification within a given sub-
type may be clinically relevant.
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Figure 2. Proliferation status predicts the PDX engraftment and further refines CMS2 classification. (a) Heatmap showing genes differentially expressed
between tumors with and without successful engraftment. (b, c) GSEA analysis of tumors with successful engraftment confirmed a negative association
with cell proliferation related pathways. (d) Ki67 staining from patient’s section. Positive antibody signals in the nuclei are shown in brown. (e) The
mean of Ki67-positive nuclei between tumor with positive and negative engraftment was 50% and 71%, respectively. (f) The mean of Ki67-positive
nuclei between CMS2 tumor with positive and negative engraftment was 50% and 67%, respectively. Statistics in (e) and (f) was performed with t-test.
(g) Kaplan–Meier recurrence-free survival analysis on stage II patients as a group or (h) per CMS showed that the association of Ki67 expression with
prognosis was subtype-specific. p value is calculated with the log-rank test. HR, hazard ratio. [Color figure can be viewed at wileyonlinelibrary.com]
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Altogether our current study identifies a subtype-specific
bias in the establishment of PDXs from CRC patients, leaving
the major subtype (CMS2) is strongly underrepresented. Drug
efficacy studies aimed at this subtype are therefore unlikely to
provide useful insight when an unselected set of PDX models
is used. Consequently, optimization in PDX establishment is
necessary to capture all tumor types. Combined with careful
selection of the proper PDXs, these efforts will ultimately
improve drug development strategies. Importantly, our PDX
models did reveal a surprising relation between proliferation
and recurrence rate specifically within CMS2, indicating that
CMS2 may not be a homogeneous subtype and can be further
refined. The relevance is further strengthened when consider-
ing that the CMS2 cancers that do engraft appear to be associ-
ated with poor clinical outcome.
Material and Method
Tissue processing
All tumor specimens (CO and RM) were obtained from
patients that underwent routine surgery in two medical cen-
ters: Academic Medical Centre (AMC, Amsterdam, the Neth-
erlands) and Flevo Hospital (Almere, the Netherlands).
Samples were processed in accordance with the rules and leg-
islation in the Netherlands and approved by the Medical Ethi-
cal Committee of the AMC immediately after surgery
(ranging between 1 and 3 hr).
Engraftment procedure
Subcutaneous implantation was performed on one flank of
6–8 week-old athymic nude mice (Harlan laboratories) or
(NSG) mice weighing from 18 to 25 g that were anesthetized
by a mixture of isoflurane/oxygen. Tumor growth was moni-
tored by bi-weekly measurements of the implantation sites.
The serial engraftments of each tumor were conducted when
the tumors reached a volume of 200–1,000 mm3. Animals
were housed in IVC cages at the Animal Research Institute
Amsterdam (ARIA-IWO), and all animal experiments were
carried out under protocols approved by the Animal Ethical
Committee of the AMC.
Characterization of patient tumors and corresponding PDX
model
Immunohistochemistry. Hematoxylin–eosin (Sigma) and
alcian blue according to the protocol from the manufacturer.
Ki67 antibody was used (ab15580; dilution1:5,000; Abcam,
Cambridge, United Kingdom) as previously described.16 Ki-67
percentage was defined as the percentage of tumor nuclei
showing Ki-67 staining per total of neoplastic cells counted in
three randomly selected fields of tumor.
Genetic analysis and sample identification. DNA and RNA
isolation, microsatellite stability status, CIMP, KRAS, p53, and
BRAF mutation status were analyzed as described before.17
Only samples with a tumor epithelial area above 20% were
used for DNA and RNA extraction. Detection of NRAS and
PI3KCA mutations (specifically E542K, E545G, E545K, and
H1047R) was performed as previously described.18 To confirm
that the material derived from PDX models originated from
the corresponding patient tumor, we assessed two polymor-
phic pentanucleotide markers (Penta C and Penta D) for sam-
ple identification.
Microarray data generation. Samples with RNA integrity
numbers ≥7 and A260/A280 ratio of ≥1.8 were included in
the microarray analysis. Hybridization was performed on
34 patients and 37 PDX models using the GeneTitan MC
(Affymetrix, Santa Clara, CA) according to the standard pro-
tocol of the Cologne Center for Genomics (CCG), University
of Cologne, Germany. The microarray data were normalized,
summarized, and log2 transformed using robust multiarray
analysis and batch effects were removed using Combat as
implemented in the sva package (version 3.22.0). All normali-
zation and batch effect correction was done separately for data
derived from patients and PDX models. After normalization
the probesets were annotated using the hgu133plus2.db anno-
tation package (version 63).19 In case of multiple probesets
interrogating a specific gene, the probeset with the highest
mean intensity was selected as representative for that gene.
The data set has been deposited in the Gene Expression
Omnibus (GEO) repository under the accession number
GSE100480.
CMS stratification of CRC tumors. The patient tumors were
CMS stratified using a support vector machine (SVM) classi-
fier trained on a data set of 466 CMS stratified CRC tumors
(GSE39582). The expression data for GSE39582 were down-
loaded from the NCBI GEO gene expression repository and
the data were normalized, batch corrected, and annotated as
described earlier in the section. CMS labels for the tumor
samples were obtained from Guinney et al.8 Only genes with
sufficient variation (standard deviation > 0.25) were included
in the next step where the most relevant genes were selected
for the final classifier construction (i.e., feature selection). This
selection was performed using iterative resampling (without
replacement) where 80% of CMS classified samples were ran-
domly selected and used to identify the top100 genes that
were most differentially expressed in one CMS class versus the
other three CMS classes. Differential expression was deter-
mined using the limma R package20 and gene ranking was
done on Benjamini-Hochberg corrected p values. Doing this
for all four CMS classes resulted in 400 selected genes per iter-
ation. After 1,000 iterations, we retained genes that were
selected in at least 250 iterations for final classifier construc-
tion (450 genes) and used those genes to construct a SVM
classifier (e1071 R package, version 1.6-8)21 with all 466 CMS
stratified samples in GSE39582. Tumor samples with a classi-
fication probability >0.5 were assigned a CMS label (33 of
34 tumors, 97%).
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Correlation analysis. For the correlation analysis, genes were
selected that showed similar expression patterns in patient
tumors and PDX models using the correlation of correlation
approach.8 All genes with a correlation of correlations coeffi-
cient >0.25 were selected for further analysis. For the correla-
tion analysis, 1,000 genes were selected that showed the
highest standard deviation in the PDX samples to ensure suffi-
cient variation. After gene-wise mean-centering is done sepa-
rately for patient tumors and PDX tumors, the Pearson
correlation between samples was calculated.
Gene set enrichment analysis (GSEA). GSEA was performed
using a selection of genesets (c5.bp.v5.1.entrez.gmt) from
MSigDB (http://www.broadinstitute.org/gsea/) release 5.1.22
The analysis was done using the GSA procedure with 10,000
permutations as implemented in the GSA R package (version
1.03). Enrichment score plots were made with the GSEA desk-
top application.
Ki67 stratification. The Ki67 stratification was done using
the median expression of Ki67 (MKI67). Samples with an
expression level ≥ median expression were assigned to the
Ki67 high group, those with an expression < median expres-
sion to the Ki67 low group. The survival distributions for the
groups were compared to the log-rank test tumor subtypes.
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